Ataxia Telangiectasia
Conditions
Keywords
AT, Ataxia, Telangiectasia
Brief summary
This research is being done to find out if Baclofen, a medicine that is often used for the treatment of abnormal stiffness, might also be useful to treat some of the neurologic problems caused by ataxia telangiectasia (A-T). The investigators also want to find out if there are better ways to measure the problems of ataxia and abnormal eye movement for future studies of medication in ataxia telangiectasia.
Interventions
DRUGBaclofen
Drug given by orally via capsules. Escalation steps in 4-day intervals. Step 1: 5mg QAM. Step 2: 5mg BID. Step 3: 5mg TID. Step 4: 10mg QAM, 5mg BID. Step 5: 10mg BID, 5mg QMid-day. Step 6: 10mg TID. Step 6 will last up to 2 weeks. De-escalation will start from highest dose step and work backwards in 2-day intervals. Complete drug administration of escalating, staying constant at 10mg TID and de-escalating will be done with both drug and placebo.
DRUGPlacebo
placebo drug
Sponsors
Johns Hopkins University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Teenagers over 12 years old and young adults with A-T may join if they have been evaluated previously in the A-T Clinical Center at Johns Hopkins Hospital and have a measurable abnormality of eye movement. * Patients who are presently taking Baclofen will be eligible for the study if they are presently receiving the medication under the direction of Dr. Crawford in the ATCC, and are willing to withdraw from the medication for a period of one month prior to the initial screening visit. * Female patients who are sexually active will be given a standard serum HCG pregnancy test. * Those who are sexually active will be counseled about necessary precautions against pregnancy during the duration of the trial.
Exclusion criteria
* A positive pregnancy test.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in the decay constant for velocity storage as assessed by quantitative video examination of eye movement during and after rotation. | 3 months |
Secondary
| Measure | Time frame |
|---|---|
| Other outcome measures include quantitative measurement of tremor, postural stability and a standard neurologic examination. | 3 months |
Countries
United States
Outcome results
None listed